NASDAQ:ARAV Aravive (ARAV) Stock Forecast, Price & News $1.70 +0.07 (+4.29%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$1.56▼$1.7350-Day Range$1.42▼$2.3052-Week Range$0.58▼$2.46Volume486,826 shsAverage Volume253,528 shsMarket Capitalization$101.75 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Aravive MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside441.2% Upside$9.20 Price TargetShort InterestBearish7.60% of Shares Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment0.74Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.26) to ($1.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector687th out of 1,006 stocksPharmaceutical Preparations Industry350th out of 492 stocks 3.5 Analyst's Opinion Consensus RatingAravive has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.20, Aravive has a forecasted upside of 441.2% from its current price of $1.70.Amount of Analyst CoverageAravive has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted7.60% of the outstanding shares of Aravive have been sold short.Short Interest Ratio / Days to CoverAravive has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.Change versus previous monthShort interest in Aravive has recently increased by 5.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAravive does not currently pay a dividend.Dividend GrowthAravive does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAravive has received a 75.78% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Aravive is -0.55. Previous Next 2.6 News and Social Media Coverage News SentimentAravive has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aravive this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for ARAV on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows2 people have added Aravive to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aravive insiders have not sold or bought any company stock.Percentage Held by Insiders60.00% of the stock of Aravive is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.85% of the stock of Aravive is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aravive are expected to decrease in the coming year, from ($1.26) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aravive is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aravive is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Aravive (NASDAQ:ARAV) StockAravive, Inc. operates as a clinical stage biotechnology company, which engages in the development of transformative treatments designed to halt the progression of life threatening disease, including cancer and fibrosis. The company was founded on December 10, 2008 and is headquartered in Houston, TX.Read More Receive ARAV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter. Email Address ARAV Stock News HeadlinesMay 25, 2023 | finance.yahoo.comAravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023May 25, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sonnet BioTherapeutics Holdings (SONN), Aravive (ARAV) and Cyclacel Pharmaceuticals (CYCC)May 31, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.May 25, 2023 | msn.comAnalyst Expectations for Aravive's FutureMay 24, 2023 | msn.comAravive: Very Small Company With Late Stage Trial In Ovarian CancerMay 18, 2023 | markets.businessinsider.com7 Short-Interest Stocks to Target for Explosive GainsMay 18, 2023 | msn.comCantor Fitzgerald Reiterates Aravive (ARAV) Overweight RecommendationMay 17, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for Aravive, Inc. (NASDAQ:ARAV) Issued By HC WainwrightMay 31, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.May 16, 2023 | finance.yahoo.comAravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell CarcinomaMay 16, 2023 | americanbankingnews.comAravive, Inc. (NASDAQ:ARAV) to Post Q2 2023 Earnings of ($0.31) Per Share, William Blair ForecastsMay 15, 2023 | finance.yahoo.comAre Medical Stocks Lagging Boston Scientific (BSX) This Year?May 12, 2023 | msn.comEF Hutton Reiterates Aravive (ARAV) Buy RecommendationMay 12, 2023 | finance.yahoo.comAravive First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsMay 12, 2023 | msn.comHC Wainwright & Co. Reiterates Aravive (ARAV) Buy RecommendationMay 11, 2023 | msn.comUnusual Put Option Trade in Aravive (ARAV) Worth $337.50KMay 10, 2023 | msn.comRecap: Aravive Q1 EarningsMay 10, 2023 | finance.yahoo.comAravive Reports First Quarter 2023 Financial Results and Provides Corporate UpdatesMay 9, 2023 | americanbankingnews.comAravive (ARAV) to Release Quarterly Earnings on WednesdayMay 8, 2023 | finance.yahoo.comAravive to Host Virtual KOL Event on its Late-Stage Oncology Asset BatiraxceptApril 26, 2023 | finance.yahoo.comAravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual MeetingApril 17, 2023 | finance.yahoo.comWhat Makes Aravive (ARAV) a New Buy StockApril 11, 2023 | finance.yahoo.comAravive Appoints Carolina Petrini as Chief Commercial OfficerApril 4, 2023 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Aravive (ARAV)March 31, 2023 | americanbankingnews.comAravive, Inc. (NASDAQ:ARAV) Short Interest Up 16.0% in MarchMarch 22, 2023 | americanbankingnews.comWilliam Blair Equities Analysts Raise Earnings Estimates for Aravive, Inc. (NASDAQ:ARAV)March 21, 2023 | americanbankingnews.comAravive, Inc. (NASDAQ:ARAV) Expected to Post Q1 2023 Earnings of ($0.30) Per ShareSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ARAV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter. Email Address ARAV Company Calendar Last Earnings3/15/2023Today5/31/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARAV CUSIPN/A CIK1513818 Webwww.aravive.com Phone(936) 355-1910FaxN/AEmployees17Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.20 High Stock Price Forecast$12.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+421.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,320,000.00 Net Margins-1,187.30% Pretax Margin-1,187.30% Return on Equity-1,865.78% Return on Assets-157.42% Debt Debt-to-Equity RatioN/A Current Ratio1.93 Quick Ratio1.93 Sales & Book Value Annual Sales$9.14 million Price / Sales10.67 Cash FlowN/A Price / Cash FlowN/A Book Value($0.65) per share Price / Book-2.51Miscellaneous Outstanding Shares59,850,000Free Float23,938,000Market Cap$97.56 million OptionableOptionable Beta2.35 Key ExecutivesGail Frances McIntyrePresident, Chief Executive Officer & DirectorLeonard Scott DoveChief Operating OfficerRudy C. HowardChief Financial & Accounting OfficerRobert B. GellerChief Medical OfficerMaria Carolina PetriniChief Commercial OfficerKey CompetitorsDecibel TherapeuticsNASDAQ:DBTXAnixa BiosciencesNASDAQ:ANIXLeap TherapeuticsNASDAQ:LPTXEton PharmaceuticalsNASDAQ:ETONBioLineRxNASDAQ:BLRXView All CompetitorsInstitutional OwnershipGeode Capital Management LLCBought 72,431 shares on 5/16/2023Ownership: 0.360%Jane Street Group LLCBought 20,728 shares on 5/16/2023Ownership: 0.105%State Street CorpBought 26,000 shares on 5/16/2023Ownership: 0.097%Susquehanna International Group LLPSold 11,800 shares on 5/16/2023Ownership: 0.000%Two Sigma Advisers LPBought 66,400 shares on 5/15/2023Ownership: 0.268%View All Institutional Transactions ARAV Stock - Frequently Asked Questions Should I buy or sell Aravive stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARAV shares. View ARAV analyst ratings or view top-rated stocks. What is Aravive's stock price forecast for 2023? 5 Wall Street research analysts have issued 12-month price targets for Aravive's stock. Their ARAV share price forecasts range from $2.00 to $12.00. On average, they expect the company's stock price to reach $9.20 in the next year. This suggests a possible upside of 464.4% from the stock's current price. View analysts price targets for ARAV or view top-rated stocks among Wall Street analysts. How have ARAV shares performed in 2023? Aravive's stock was trading at $1.32 at the beginning of the year. Since then, ARAV stock has increased by 23.5% and is now trading at $1.63. View the best growth stocks for 2023 here. When is Aravive's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ARAV earnings forecast. How were Aravive's earnings last quarter? Aravive, Inc. (NASDAQ:ARAV) announced its quarterly earnings results on Wednesday, March, 15th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.13. The firm had revenue of $1.47 million for the quarter, compared to analyst estimates of $0.37 million. Aravive had a negative net margin of 1,187.30% and a negative trailing twelve-month return on equity of 1,865.78%. What other stocks do shareholders of Aravive own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arbutus Biopharma (ABUS) and BioCryst Pharmaceuticals (BCRX). What is Aravive's stock symbol? Aravive trades on the NASDAQ under the ticker symbol "ARAV." Who are Aravive's major shareholders? Aravive's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.36%), BlackRock Inc. (0.35%), Assenagon Asset Management S.A. (0.33%), Two Sigma Advisers LP (0.27%), Renaissance Technologies LLC (0.26%) and Jane Street Group LLC (0.11%). Insiders that own company stock include Amato Giaccia, Gail Frances Mcintyre and Vinay Shah. View institutional ownership trends. How do I buy shares of Aravive? Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aravive's stock price today? One share of ARAV stock can currently be purchased for approximately $1.63. How much money does Aravive make? Aravive (NASDAQ:ARAV) has a market capitalization of $97.56 million and generates $9.14 million in revenue each year. The company earns $-76,320,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis. How can I contact Aravive? Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The official website for the company is www.aravive.com. The company can be reached via phone at (936) 355-1910 or via email at christina@sternir.com. This page (NASDAQ:ARAV) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.